Theravance Biopharma (TBPH) shares ended the last trading session 8.3% higher at $10.47. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.9% loss over the past four weeks.
The company has developed Yupelri, a nebulized treatment for chronic obstructive pulmonary disease, in collaboration with Viatris. Theravance is also developing ampreloxetine in late-stage studies for treating neurogenic orthostatic hypotension in patients with multiple system atrophy. The growing optimism related to encouraging pipeline progress, along with the uptake of Yupelri, might have driven the recent share price rally.
This biopharmaceutical company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of -266.7%. Revenues are expected to be $35.19 million, up 100.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Theravance Bio, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TBPH going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Theravance Bio is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, electroCore, Inc. (ECOR), finished the last trading session 7.4% higher at $17.01. ECOR has returned -5.5% over the past month.
For electroCore
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpTheravance Biopharma, Inc. (TBPH) : Free Stock Analysis Report
electroCore, Inc. (ECOR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
